Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line

Artif Cells Nanomed Biotechnol. 2018 Mar;46(2):293-302. doi: 10.1080/21691401.2017.1307212. Epub 2017 Mar 31.

Abstract

Here, we investigated the effects of dual delivery of IGF-1R siRNA and doxorubicin by chitosan nanoparticles on viability of A549 lung cancer cells line by utilization of MTT and qRT-PCR. Furthermore apoptosis and migration of treated cells were assessed by Annexin-PI and wound healing assays, respectively. The chitosan nanoparticles had about 176 nm size with zeta potential and polydispersive index about 11 mV and 0.3, respectively. The IGF-1R siRNA had synergistic effect on DOX-induced cytotoxicity and apoptosis in tumour cells. In addition, siRNA/DOX-loaded chitosan nanoparticles could significantly decrease migration and expressions of mmp9, VEGF and STAT3 in A549 cells.

Keywords: Chitosan nanoparticle; IGF-1R; doxorubicin; lung cancer; ss siRNA.

MeSH terms

  • A549 Cells
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Cell Movement / drug effects
  • Cell Movement / genetics
  • Chitosan / chemistry*
  • Down-Regulation / drug effects
  • Down-Regulation / genetics
  • Doxorubicin / chemistry*
  • Doxorubicin / pharmacology
  • Drug Carriers / chemistry
  • Drug Liberation
  • Humans
  • Hydrogen-Ion Concentration
  • Lung Neoplasms / pathology*
  • Matrix Metalloproteinase 9 / genetics
  • Nanoparticles / chemistry*
  • Neoplasm Invasiveness
  • RNA, Small Interfering / chemistry*
  • RNA, Small Interfering / genetics
  • Receptor, IGF Type 1 / deficiency*
  • Receptor, IGF Type 1 / genetics*
  • STAT3 Transcription Factor / genetics
  • Vascular Endothelial Growth Factor A / genetics

Substances

  • Drug Carriers
  • RNA, Small Interfering
  • STAT3 Transcription Factor
  • Vascular Endothelial Growth Factor A
  • Doxorubicin
  • Chitosan
  • Receptor, IGF Type 1
  • Matrix Metalloproteinase 9